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http://www.translational-medicine.com/content/12/1/41RESEARCH Open AccessGeneration of orthotopic patient-derived
xenografts from gastrointestinal stromal tumor
Jason K Sicklick1*, Stephanie Y Leonard1, Michele L Babicky1, Chih-Min Tang1, Evangeline S Mose1,
Randall P French1, Dawn V Jaquish1, Carl K Hoh2, Michael Peterson3, Richard Schwab4 and Andrew M Lowy1Abstract
Background: Gastrointestinal stromal tumor (GIST) is the most common sarcoma and its treatment with imatinib
has served as the paradigm for developing targeted anti-cancer therapies. Despite this success, imatinib-resistance
has emerged as a major problem and therefore, the clinical efficacy of other drugs has been investigated. Unfortunately,
most clinical trials have failed to identify efficacious drugs despite promising in vitro data and pathological responses in
subcutaneous xenografts. We hypothesized that it was feasible to develop orthotopic patient-derived xenografts (PDXs)
from resected GIST that could recapitulate the genetic heterogeneity and biology of the human disease.
Methods: Fresh tumor tissue from three patients with pathologically confirmed GISTs was obtained immediately
following tumor resection. Tumor fragments (4.2-mm3) were surgically xenografted into the liver, gastric wall, renal
capsule, and pancreas of immunodeficient mice. Tumor growth was serially assessed with ultrasonography (US) every
3-4 weeks. Tumors were also evaluated with positron emission tomography (PET). Animals were sacrificed when they
became moribund or their tumors reached a threshold size of 2500-mm3. Tumors were subsequently passaged, as well
as immunohistochemically and histologically analyzed.
Results: Herein, we describe the first model for generating orthotopic GIST PDXs. We have successfully xenografted
three unique KIT-mutated tumors into a total of 25 mice with an overall success rate of 84% (21/25). We serially followed
tumor growth with US to describe the natural history of PDX growth. Successful PDXs resulted in 12 primary xenografts
in NOD-scid gamma or NOD-scid mice while subsequent successful passages resulted in 9 tumors. At a median of 7.9
weeks (range 2.9-33.1 weeks), tumor size averaged 473±695-mm3 (median 199-mm3, range 12.6-2682.5-mm3) by US.
Furthermore, tumor size on US within 14 days of death correlated with gross tumor size on necropsy. We also
demonstrated that these tumors are FDG-avid on PET imaging, while immunohistochemically and histologically
the PDXs resembled the primary tumors.
Conclusions: We report the first orthotopic model of human GIST using patient-derived tumor tissue. This novel,
reproducible in vivo model of human GIST may enhance the study of GIST biology, biomarkers, personalized cancer
treatments, and provide a preclinical platform to evaluate new therapeutic agents for GIST.
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Gastrointestinal stromal tumor (GIST), the most com-
mon gastrointestinal mesenchymal tumor, afflicts 12-20
patients per million annually [1]. Unlike many other
cancers, the genomic and molecular events driving GIST
are well characterized. These include mutations in sev-
eral protein kinase genes including KIT, PDGFRα, and
BRAF that are known to regulate fundamental processes
in oncogenesis including tumor proliferation, metastasis,
neo-vascularization, and chemo-resistance [2-4]. GIST
has served as a paradigm for the development of tar-
geted cancer therapies because inhibition of KIT and
PDGFRα has resulted in therapeutic benefit. At present,
the first-line treatment for patients with metastatic,
unresectable or resected high-risk GIST is imatinib
(Gleevec, Novartis, Basel, Switzerland) [5-7], a small
molecule inhibitor of tyrosine kinases including KIT
(c-KIT, CD117) and BCR-ABL. This drug has been
shown to have profound therapeutic benefit with a
favorable toxicity profile. Because of these qualities, ima-
tinib is often cited as the prototype for targeted thera-
peutics development.
Beyond our knowledge that KIT mutations drive GIST
sarcomagenesis, it is now known that specific KIT muta-
tions are both prognostic and predictive of responses to
the current kinase inhibitors. For example, KIT Exon 9
mutations are associated with more aggressive phenotypes
and imatinib insensitivity as compared to KIT exon 11 mu-
tations [4,8]. Secondary resistance to imatinib, which oc-
curs in half of patients after 20 months of therapy, is most
commonly caused by acquired, non-randomly distributed
single nucleotide KIT mutations within the ATP binding
pocket (exons 13 and 14) and the kinase activation loop
(exons 17 and 18) [9-12]. Sunitinib (Sutent, Pfizer, New
York, NY), a multikinase inhibitor with activity against
PDGFR, VEGFR and KIT, is employed as second line ther-
apy for GIST. Clinical trials have shown that in imatinib-
resistant cases, only 12-19% of sunitinib-treated patients
have significant responses [13,14]. These anti-GIST therap-
ies were developed based upon efficacy data in vitro or
in vivo using subcutaneous models of tumor implantation.
However, once a patient progresses on sunitinib, treatment
options are limited as evidenced by two recent, large
clinical trials which reported on the efficacy of dasatinib
(Bristol-Myers Squibb, New York, NY), a combined Src
and BCR-ABL inhibitor, and regorafenib (Bayer, Pittsburgh,
PA), a combined VEGFR2 and TIE2 inhibitor [15,16].
Dasitinib failed to show any benefit in this patient popula-
tion while in the Phase III GRID trial of regorafenib, 62%
of patients developed resistance to the drug, and conse-
quently disease progression by the sixth month of therapy
[17]. This highlights the urgency for developing more
effective agents to treat GIST [18], as well as more broadly
applicable preclinical models to accomplish this goal.Despite the importance of preclinical studies on GIST
tumorigenesis and resistance mechanisms, there are cur-
rently limited model systems for studying this disease
in vitro and in vivo. For instance, two GIST cell lines
with KIT exons 11 and 13 mutations have been reported
in the literature; [19,20] however, the second most com-
mon KIT mutation (e.g., exon 9) lacks a corresponding
cell line for in vitro assays. Moreover, there are no cell
lines which contain any exon 14 or 18 mutations while
most of the common exon 17 mutations are not present
in cell lines except with overexpression vectors often
used in non-GIST lines, such as BaF3 cells. In addition,
no cell lines exist which contain either PDGFRα mutation/
deletions/insertions or BRAFV600E mutations that also
cause GIST. Regarding mouse models of GIST, sub-
cutaneous (SQ) xenografts have been utilized as the
prototype in nude mice [21-23]. However, because tumor
growth or responses to drug treatment observed in SQ
xenograft models are often different from those observed
in an orthotopic environment, two groups have developed
transgenic mouse models of GIST. Rubin and colleagues
identified a KITK641E mutation (exon 13) in sporadic hu-
man GISTs and in the germ line of familial GIST syn-
drome patients [24]. They then generated homozygous
and heterozygous KITK641E transgenic mice that develop
cecal GISTs with complete penetrance. However, in
humans, cecal (e.g., colonic) GISTs are quite rare, suggest-
ing that this model does not completely recapitulate the
human disease. Additionally, Besmer and colleagues de-
veloped a second model via a knock-in strategy by intro-
ducing a KIT exon 11 mutation (V558Δ/+) into the mouse
genome [25]. While the latter transgenic model is more
representative of the human disease, it only embodies a
mutation that is well studied, evaluable in the GIST-T1
cell line, and sensitive to imatinib.
Despite the aforementioned models, there remains a
gap in our ability to predict effective drugs or study the
biology of the less frequent, but often drug-resistant,
gene mutations in GIST. Therefore, our goal was to
develop a reproducible, orthotopic patient-derived xeno-
graft model of GIST. This novel model for studying
GIST in vivo recapitulates the intra-abdominal micro-
environment in which GIST arises and allows for the
study of the increasingly appreciated heterogeneity in the
biology of GIST. It is our hope that this model may serve
as a valuable resource for personalized cancer therapy and
the evaluation of new therapeutic agents for GIST.
Materials and methods
Animal studies
NOD-scid (NS) and NOD-scid IL2Rgammanull (NOD-scid
gamma, NSG) mice at 8-10 weeks of age were obtained
from the Jackson Laboratory (Bar Harbor, Maine). NS
homozygous mice harboring a spontaneous Prkdcscid
Table 1 Patient demographics
Number
Age
Mean 62 years
Range 46 – 72 years
Gender
Male 2
Female 1
Location of primary tumor
Stomach 0
Small bowel 3
Duodenum 1
Jejunum 1
Ileum 1
Presentation
Abdominal pain 2
Bleeding 1
Recurrence/metastasis on CT scan 1
Previous imatinib therapy
Yes 1
No 2
Primary tumor size
Mean 19.2 cm
Range 6.5 – 38.0 cm
Mitotic index (mitoses per 5 mm2)
Mean 32.7
Range 10 – 65
Peritoneal metastases
Yes 2
No 1
KIT exon mutational analysis
Exon 9 2
Exon 11 1
Exon 13/14 0
Exon 17/18 0
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for severe combined immune deficiency characterized
by an absence of functional T cells and B cells, hypogam-
maglobulinemia, lymphopenia, and a normal hematopoietic
microenvironment. NSG mice combine the features of the
NOD/ShiLtJ background, the severe combined immune
deficiency mutation and an IL2 receptor gamma chain
deficiency. As a result, this NSG strain (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ), lacks functional T cells, B cells, and NK
cells, as well as is deficient in cytokine signaling. Conse-
quently, this NSG strain performs better in engraftment
of human hematopoietic stem cells and peripheral-blood
mononuclear cells than any other published mouse strains
[26-31]. Moreover, these recent publications have dem-
onstrated this strain’s utility in the study of solid tumor
xenografts and cancer stem cell engraftment.
All research mice were maintained in a barrier facility
under HEPA-filtered air with food and water available
ad libitum. Food, water and cage bedding were sterilized
prior to use. Temperature (20-21°C), humidity (50-60%)
and 12-hour light-dark cycle were controlled. Animals
were manipulated under sterile conditions during surgery.
Animal experiments fulfilled National Institutes of Health
and University of California, San Diego (UCSD) require-
ments for humane animal care. The UCSD Institutional
Animal Care and Use Committee approved experimen-
tal methods.
Sourcing of human tumor tissue
Tumor acquisition/banking is routinely performed for
all GIST operations under our Institutional Review
Board (IRB) approved protocol (#090401). Written in-
formed consent was obtained from all patients prior to
sample collection. Three patients with KIT-mutated GIST
underwent operations in 2011. All patients’ demographics
were listed in Table 1. The tumor tissue for xenografts
was obtained at the time of tumor resection after a
pathologist acquired tissue that was needed for the
patient’s routine clinical care and confirmed the histo-
logic diagnosis. Additional tissue was banked in our
biorepository. Excess fresh tumor was used for immedi-
ate xenografting into mice. All surgically resected
tumor fragments were stored in sterile specimen cups
and expeditiously transported from the operating room
to our laboratory on ice. Staining for clinical diagnosis
included hematoxylin and eosin (H&E), KIT and DOG-
1. Genetic materials derived from tumors were analyzed
by ARUP Laboratories (Salt Lake City, UT) for KIT and
PDGFRα mutations.
Implantation of patient-derived xenografts
Tumor was dissected into 2×2 mm fragments (4.2 mm3)
and placed in a petri dish kept on ice containing sterile,
antibiotic-free DMEM media (Mediatech, Manassas, VA)until implantation. NS and NSG mice were anesthetized
with intraperitoneal injection of ketamine:xylazine cock-
tail (60-mg/kg : 10-mg/kg). They were then placed in
the supine position on a warm pad to maintain body
temperature. Once mice were sedated, the abdominal
wall was shaved and cleansed with 70% alcohol and
betadine. A 1-2-cm midline incision was made through
the skin, fascia and peritoneum. Surgical sutures (6-0
silk) were used to implant 2×2 mm tumor fragments
onto the livers, gastric walls, renal capsules, or lesser
sacs (peri-pancreatic area). Organs implanted with
tumor fragments were returned to the abdomen and the
Table 2 Mouse characteristics for generation of GIST
patient-derived xenografts
Number Percent (%)
Age at implantation
Mean ± standard deviation 9.1 ± 7.3 weeks
Range 5.7 – 30.6 weeks
Gender
Male 8 32.0%
Female 17 68.0%
Genotype
NOD-scid (NS) 10 40.0%
NOD-scid gamma (NSG) 15 60.0%
Tumor development
Yes 21 84.0%
No 4 16.0%
Passages
0 (Primary, successes/total) 11/14 85.7%
1 (Successes/total) 5/6 83.3%
2 (Successes/Total) 5/5 100.0%
Location of implantation
Successful implantations/total 21/25 84.0%
Liver (successes/total) 9/10 90.0%
Renal capsule (successes/total) 9/10 90.0%
Lesser sac (successes/total) 2/3 66.7%
Gastric wall (successes/total) 1/2 50.0%
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suture. A total of 14 animals underwent initial tumor
implantation of freshly dissected human tumor tissues.
Mice were monitored daily for 5 consecutive days after
surgery with particular attention paid to animal distress,
wound dehiscence, and signs of infection. Thereafter,
they were examined 2-3 times per week. Three researchers
(SL, CT and EM) assessed tumor progression by palpation
twice a week. Tumor progression was also evaluated by
ultrasound every 3-4 weeks as described in the “Tumor
Imaging” section. Animals were euthanized based on
either tumor volume (threshold 2500 mm3) as determined
by ultrasound or clinical status during the observation
period as specified in our IACUC-approved protocol. A
necropsy was performed on the animals after euthanasia
to assess the presence and distribution of tumors. Tumors
were harvested and fixed in 10% formalin for histological
and immunohistological analyses. Harvested tumors were
also subject to serial passages into additional 11 mice. All
3 patient-derived xenografts were successfully passaged up
to twice in order to determine the ability to perpetuate
and expand these tumors for extended periods of time.
This provides the potential for developing a model that is
based upon a small amount of available tumor, which can
be utilized for current and future studies. Mouse charac-
teristics for tumor implantation are listed in Table 2.
Tumor imaging
Tumors were serially imaged with Visual Sonics Vevo
770 ultrasound machine (VisualSonics Inc, Toronto,
Canada) every 3-4 weeks by a single, experienced ultra-
sonographer. Mice were kept anesthetized using con-
tinuous isoflurane inhalation. Prior to ultrasonography,
abdominal wall hair was removed from the skin overlying
the tumor implant area with clippers and hair removal
cream. Their skin was then covered with an aqueous
ultrasonic gel and a high frequency transducer (RMV706)
at 20-60 MHz range was used for imaging. Tumor detec-
tion was recorded as cine loops of ultrasound images.
Digital images were reviewed to select the tumors’ largest
cross-sectional diameters (e.g., length and width) from
a single image frame. Tumor volume was calculated as
(π/6) × (length × width)3/2 [32].
Two animals were also evaluated with Positron Emission
Tomography (PET, GE eXplore Vista DR PET scanner).
Mice were anesthetized by isoflurane inhalation and
placed on an imaging bed controlled by a computer in
order to insert into the ring-type gantry. They were then
administered a radiopharmaceutical fluorodeoxyglucose-
[18F] (F-18 FDG) delivered by tail vein injection. F-18
FDG is used for the assessment of glucose metabolism,
and therefore serves as an indicator for high metabolic
activity of tissue, such as malignant tumors. One mouse
was given 250 μCi in 113 μL while another mousereceived 395 μCi in 200 μL. A sequence of successive
whole-body images was acquired in the 3D mode using
the system software. DICOM images were analyzed by an
experienced nuclear medicine radiologist (CKH) for
tumor standardized uptake values (SUVs).
Histopathology and immunohistochemistry
Serial sections of formalin-fixed, paraffin-embedded
(FFPE) resected xenografts, 10-μm thick, were used for
histopathology analyses by H&E staining. For all tumors,
the histological diagnoses were confirmed under light
microscopy by an experienced pathologist. Sections
for immunohistochemical staining were treated twice
with 0.3% Triton X-100 (Sigma-Aldrich) in PBS for 10
minutes and then in 0.3% hydrogen peroxide solution
in order to block endogenous peroxidase activity. The
sections were then blocked with serum followed by an
Avidin-Biotin blocking reagent (Vector Laboratories;
Burlingame, CA) in order to inhibit non-specific binding
in the tissue. The sections were then incubated with
polyclonal rabbit anti-human CD117 (c-KIT) antibody
(1:50, Dako North America, Carpinteria, CA) overnight
at 4°C. Sections were next incubated with biotinylated
secondary antibody and ABC reagents of the Vectastain
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instructions (Vector Laboratories). The secondary anti-
body was detected using the Avidin-Biotin-Peroxidase
method with 3,3′-diaminobenzidine as the substrate
(Vector Laboratories). Negative controls were performed
by omitting the primary antibody and/or using isotype
control antibody.
Statistical analysis
Comparisons between groups were performed using
Prism 4 (GraphPad, La Jolla, CA). Results are reported
as mean ± standard deviation (s.d.) or standard error
of the mean (s.e.m.) as appropriate. Comparison data
were analyzed for significance using the Student’s t-test,
ANOVA, and Bonferroni’s multiple comparison test.
Statistical significance was accepted at the 5% level and
statistical trends were accepted at the 10% level.
Results
Sourcing human GISTs
To our knowledge, only subcutaneous (SQ) GIST xeno-
grafts have been performed in mice. We hypothesized
that human GISTs could be intraperitoneally (IP) xeno-
grafted into immunodeficient mice in order to better
recapitulate the biology of GIST, a disease which tends
to metastasize to the liver and peritoneum, but not the
soft tissue of the flank. KIT-mutated GIST tissue from
three patients was used for xenografts in this studyA B
D
KIT 4×
Figure 1 Resection of a 13-cm GIST from a 46-year old man that pres
heterogeneous mass in the left abdomen. B. PET-CT demonstrating an FDG
resection of the third and fourth portions of the duodenum and proximal
GIST with strong KIT immunostaining. E. H&E staining demonstrating 23 m(Table 1). This included tumors from 2 male patients
and 1 female patient with mean age of 62. Their primary
tumors were all found in the small bowel. One patient
had a clinical presentation of worsening abdominal pain
while the second patient presented with acute onset
abdominal pain due to intratumoral bleeding. The third
patient had GIST recurrence and metastatic tumors
detected by CT scan. Only the latter patient had previ-
ously received imatinib therapy. The mean tumor size
was 19.2 cm (range: 6.5 - 38.0 cm) with an average
mitotic index (mitoses per 50 high-power fields equals
mitoses per 5 mm2) of 32.7 (range: 10 - 65). Based upon
pathological examination, one patient had stage IIIB and
the other two patients had stage IV GIST with peritoneal
involvement. Genetic sequencing analyses revealed that
two tumors had KIT exon 9 mutations and one tumor
had an exon 11 mutation. Herein, we present a represen-
tative case of a 46-year old male patient (Figure 1). The
patient was first examined by CT scan and found to have
a heterogeneous tumor mass in the left upper quadrant
of the abdomen (Figure 1A) which was FDG-avid on
PET-CT scan (Figure 1B). He underwent surgical resec-
tion of a 13.0 × 11.0 × 10.0 cm GIST removed from the
fourth portion of the duodenum and the proximal jejunum
(Figure 1C). Histologically the tumor tissue had strong
KIT (Figure 1D) and DOG-1 staining (data not shown),
consistent with GIST. This tumor had mixed spindle cell
and epithelioid histology, as well as a mitotic index of 23C
E
H&E 40×
ented with abdominal pain. A. CT of the abdomen demonstrates a
-avid mass in the left upper quadrant. C. Gross specimen following
jejunum where the tumor was arising. D. Pathology consistent with a
itoses (arrows) per 50 high power fields.
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other two tumors also had high-risk features.
Development of GIST PDXs
To develop a novel xenograft model of GIST in vivo,
fresh human tumor tissues were implanted within im-
munodeficient mice. We employed a midline laparotomy
to suture 2×2 mm tumor fragments into the abdominal
viscera of NS (N = 10) and NSG (N = 15) mice. This
included 14 primary xenografts and 11 passaged xeno-
grafts. Fresh tumor tissues implanted into 14 mice were
defined as Passage zero (P0). Tumor tissues were har-
vested from P0 mice and implanted into 6 mice as
Passage 1 (P1); and subsequently another xenograft with
P1 tumors was carried out in 5 mice as Passage 2 (P2).
Xenografts were performed in 25 mice with an 84%
(21/25) success rate which included a 4% (1/25) peri-
operative mortality in a P2/NS mouse. Different implant-
ation sites were compared for xenograft efficiency. We
observed tumor growth and progression in the liver
(9/10), renal capsule (9/10), lesser sac (2/3), and gastric
wall (1/2). There was no tumor growth in three mice
with the following characteristics: P0/NSG/Kidney; P1/
NSG/Liver; and P0/NS/Stomach. Detailed characteristics
of the mice used for the PDXs are shown in Table 2.
Natural history of GIST orthotopic PDXs
Given the intra-abdominal location of tumors, standard
calipers cannot be employed to monitor tumor growth.
Therefore, in order to monitor the natural history of
tumor progression, ultrasound (US) imaging was con-
ducted every 3-4 weeks after implantation. As shown in
Figure 2A, one tumor in the liver reached 7 × 2.4 mm in
size as determined by US at 4 weeks. By 7 weeks, the
same mouse had to be terminated due to poor health.
The tumor was harvested (Figure 2B-C) and passaged
into additional NS mice. In the entire cohort, PDX
tumor size (as determined by US imaging) at 2.9-33.1
weeks (median 7.9 weeks) averaged 473 ± 695 mm3A B
Figure 2 Generation of GIST xenografts. Tumor was xenografted into th
mice. Using ultrasound, we followed tumor progression. A. At 4 weeks, one
upon ultrasound examination. B-C. At 7 weeks, the same mouse became d
two NOD-scid mice. The tumor is noted at the end of the cotton swab. 6-0(median 199 mm3, range 12.6-2682.5 mm3). Every surviv-
ing mouse with a PDX received at least 2 serial US studies
(mean 2.5 ± 1.7, median 2, range 0 - 7) in order to moni-
tor the natural history of their tumor growth. Based upon
maximum tumor size achieved, we could sort tumors into
two groups with distinct tumor growth patterns (Figure 3).
In general, tumors with a maximum tumor size ≥ 50 mm3
(Figure 3A, N = 11) tended to be faster growing than those
with a maximum tumor size < 50 mm3 (Figure 3B, N = 10).
However, in the former group, there were outliers that
began growing slowly but later achieved a larger final
tumor volume.
To further assess the how tumor passage, immunode-
ficient mouse type, and tumor implantation location
affected maximum tumor size, we performed subgroup
analyses of the 21 mice that developed tumors (Figure 4).
P1-2 tumors (829.5 ± 326.1 mm3, N = 9) were larger
than P0 tumors (187.1 ± 59.4 mm3, N = 12, P < 0.05,
Figure 4A). NS tumors (994.1 ± 329.7 mm3, N = 8) were
larger than NSG tumors (135.2 ± 56.7 mm3, N = 13,
P < 0.006, Figure 4B). Furthermore, P1-2/NS tumors
(1240.0 ± 392.5 mm3, N = 6) were larger than P0/NSG
tumors (173.2 ± 69.9 mm3, N = 10, P < 0.01) and P1-2/
NSG tumors (8.6 ± 3.6 mm3, N = 3, P < 0.05, Figure 4C).
There was no difference between P1-2/NS tumors and
P0/NS tumors (256.4 ± 87.3 mm3, N = 2) due to the
small sample size of the latter group. Comparison of the
maximum tumors sizes of the four implantation locations
(Kidney: 610.9 ± 338.5 mm3, N = 9; Liver 284.7 ± 109.1
mm3, N = 9; Pancreas 601.6 ± 554.5 mm3, N = 2; Stomach
446.4 mm3, N = 1) showed no statistically significant
differences due to variability within the groups, con-
founding factors such as passage/mouse type, or small
sample sizes (Figure 4D). However, in subgroup analyses,
the P1-2/NS mice kidney tumors (2347.6 ± 334.9 mm3,
N = 2) tended to be larger than liver tumors (770.6 ±
191.5 mm3, N = 2, P < 0.055) and pancreas tumors 601.6 ±
554.5 mm3, N = 2, P < 0.12, Figure 4E). To determine the
accuracy of our ultrasound findings, we compared theC
e livers, kidneys, lesser sacs and gastric walls of NOD-scid and NSG
tumor in the liver increased from 4 × 2 mm to 7 × 2.4 mm based
istressed and we performed a necropsy with passage of the tumor into
silk suture material can be seen at the site of implantation.
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Maximum size    50 mm3 (N=11) Maximum size < 50 mm3 (N=10)
Figure 3 Natural history of xenograft tumor progression based upon serial ultrasound imaging. Based upon maximum tumor size
achieved, tumors were sorted into two groups with distinct tumor growth patterns. A. Tumors with a maximum tumor size ≥ 50 mm3 (N = 11).
B. Tumors with a maximum tumor size < 50 mm3 (N = 10).
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weeks of their last US. There was no statistically signifi-
cant difference between the groups (US: 524.3 ± 134.6
mm3 vs. 457.2 ± 119.4 mm3, P =NS, Figure 4F).
Histological analyses of GIST PDXs
To investigate if PDXs maintain human GIST tumor
properties after implanting tumor into mice (i.e., P0) or
after passage once into additional mice (i.e., P1), six miceA
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P < 0.05 
P1-2/NS vs. P0/NSG (P < 0.01)
P1-2/NS vs. P1-2/NSG (P < 0.05)
P1-2/NS:
Kidney vs. Liver (P < 0.055)
Kidney vs.Pancreas (P < 0.12) 
Figure 4 Maximum xenograft size depends upon tumor passage, imm
A. Comparison of tumor passages (P0 vs. P1-2). B. Comparison of NSG and
NSG or NS immunodeficient mice. D. Comparison of tumor implantation si
F. Comparison of gross tumor size at necropsy with ultrasound findings obwere sacrificed and their tumor tissues were subject to
GIST histopathological analyses and KIT immunohisto-
chemical staining. Five of the six (83.3%) maintained
strong KIT staining of the tumors. It is notable that the
hallmarks of tumor necrosis were not seen in the one
spindle cell neoplasm lacking KIT expression. Thus, the
mechanism for KIT downregulation remains unknown.
Despite the presence of tumors, 4 mice were not evalu-
able histologically due to tissue necrosis overnight.B
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unodeficient mouse type, and tumor implantation site.
NS immunodeficient mice. C. Subgroup comparison of passages plus
tes. E. Comparison of tumor implantation sites in P1-2/NS mice.
tained within 2 weeks of death.
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threshold size of 2500 mm3 for sacrifice and passage,
became quite ill due to the Staphylococcal epidemic in
our vivarium. We prematurely sacrificed these mice and
the tumors tissues were used for passaging to additional
healthy mice, leaving no tissue for additional histological
analyses. However, this suggests that even in the event
of an infection or illness, tumors can be salvaged for
additional passaging and study. An example of a P0
mouse with GIST histopathology and KIT staining is
shown in Figure 5. At 21.1 weeks, this P0 mouse had an
8.5 × 7 × 6.5 mm tumor in the liver on gross examination
(Figure 5A). To verify the primary tumor histologically,
serial sections of tumor tissues were stained by H&E and
blindly reviewed by a pathologist (MP). It was evident that
a spindle cell neoplasm was present in the primary tumor
but not in the neighboring liver tissue (Figure 5B). Fur-
thermore, in contrast to the adjacent non-neoplastic
liver that lacked KIT staining, the implanted tumor had
strong KIT immunostaining signals (Figure 5C).
PET imaging of GIST PDXs
PET scan was employed to assess xenografts for human
GIST tumor properties. Two mice with tumors from the
patient 1′s FDG-avid tumor (Figure 1) were evaluated
with PET scan and both tumors were FDG-avid on PET.
As shown in Figure 6, a P0 mouse had tumor implanted
onto the right renal capsule and was subject to PET scan
at 16.1 weeks. The xenograft measured 12 × 10.5 mm
on gross examination (Figure 6B) and was FDG-avid
(SUVmax 2.2, SUVmin 1.8, SUVmean 2.0) by PET scan as
indicated by the arrow in Figure 6A. The FDG uptake in
the heart and the brown fat of the shoulder girdles serve
as a positive control. Taken together, orthotopic GIST
PDXs maintain growth capacity and properties similar to
that of patients’ GIST tumors.
Discussion
For the first time, we report an orthotopic patient-
derived xenograft (PDX) model of human GIST. ThisA B
Liver
1.2 cm 
Figure 5 Xenograft tumor progression is marked by tumor growth and
this P0 mouse was sacrificed for tumor passage. The primary tumor in the live
was performed by a pathologist. H&E staining confirmed the presence of a sp
into the liver parenchyma. C. Positive KIT immunostaining was present in themodel was developed in immunodeficient mice, includ-
ing the NOD-scid (NS) and the NOD-scid gamma
(NSG) strains. In our study, we report an 84% xenograft
success rate as a proof of concept with respect to our
novel approach to studying GIST. In both strains, we
demonstrate that multiple intraperitoneal sites are cap-
able of supporting GIST growth, with the liver and renal
capsule allowing for high rates of engraftment. More-
over, we effectively passaged PDXs at high engraftment
rates and demonstrated that high-resolution ultrasound
imaging can be employed to serially follow the natural
history of tumor growth. Furthermore, tumors passed
from NSG mice into the renal capsules of NS mice
appear to develop the most robust tumors. Finally, xeno-
grafted tumors maintain properties comparable to that
of patient’s GIST tumor tissue, including cellular hist-
ology, KIT expression and FDG-avidity on PET scan.
Tumor xenografts are frequently established by sub-
cutaneous (SQ) injection of immortalized cell lines be-
tween the dermis and underlying muscle within the
flank, back or footpad of immunodeficient mice [21,33].
For over 30 years, this model has been widely used in
cancer research because it is fast, cheap, reproducible,
and has been considered sufficient for assessing the
activity of anti-tumor agents. It also does not require
expensive imaging modalities such as US, computed
tomography (CT) or PET in order to visualize tumors
because they can be merely measured with calipers [34].
However, these models often fail to accurately predict
responses in humans since the SQ microenvironment is
not relevant to the sites of primary or metastatic disease
[35]. These observations have suggested that such tumor
models do not represent appropriate sites for modeling
human malignancies in order to evaluate responses to
anti-cancer drugs [36].
Given these deficiencies in SQ models, orthotopic
tumor xenografts are increasingly being utilized to de-
velop a model with superior clinical relevance and trans-
lation applications because these models provide: 1) a
biologically relevant site for tumor-host interactions; 2)C
GIST
10X 10X
GISTLiver
KIT immunostaining of a spindle cell neoplasm. A. At 21.1 weeks,
r measured 8.5 × 7 × 6.5 mm on gross examination. B. Blinded review
indle cell neoplasm consistent with a GIST. This tumor appears to invade
xenografted tumor but not in the adjacent non-neoplastic liver.
A B
1.2 cm 
Heart
Brown fat
(shoulder girdles)
Tumor
Figure 6 Human GIST xenografts are FDG-avid on PET scan. A. This P0 mouse underwent tumor xenografting into the right renal capsule. At 16.1
weeks after implantation, we performed imaging via PET scan. The arrow denotes tumor uptake of FDG (SUVmax 2.2, SUVmin 1.8, SUVmean 2.0) by PET scan
as indicated by the arrow in A. The FDG uptake in the heart and the brown fat of the shoulder girdles serve as a positive control. B. Gross photograph of
the corresponding FDG-avid tumor measuring 12 × 10.5 mm in the same mouse.
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gression; 3) the ability to study site-specific dependence
upon therapy; and finally, 4) organ-specific expression of
genes [36]. While this approach has clear advantages as
compared to SQ models, it is undoubtedly more expen-
sive, labor intensive, technically challenging, and requires
longer post-procedural healing and recovery [35,36].
Nonetheless, orthotopic tumor models have emerged as
the preference for many cancer researchers.
To better approximate the genetic heterogeneity of
human cancer, PDXs are now emerging as an alternative
to cell lines. Like many tumors, GISTs can be SQ im-
planted into the flanks of mice [21-23,37,38]. However,
for the aforementioned reasons, most SQ models are
unable to recapitulate human tumor biology and there-
fore have less clinical relevance [39]. While low passage
PDXs have the advantage of maintaining the tumor’s
complex genetic and epigenetic abnormalities, growing
them in a foreign tumor microenvironment (i.e., sub-
cutaneously) partially negates this advantage [35]. In
contrast, our xenograft model is a reproducible model of
human GIST that replicates the intraperitoneal micro-
environment and heterogeneity of human GISTs while
allowing for the development of models (i.e., KIT exon 9
mutated GIST) that are not currently available for study
in GIST cells or transgenic mouse models. Evidence also
suggests that, as opposed to SQ injections, orthotopic
xenografts allow for greater invasion into nearby organs,
as well as, metastases to the liver [40]. In fact, we
observed that GIST PDXs could grow and invade into
adjacent tissues, such as the liver (Figure 5B). We havenot yet observed metastases, a fact that may have been
in part due to rapid local tumor progression that neces-
sitated sacrifice of animals in compliance with IACUC
regulations. Nevertheless, our model and other orthoto-
pic xenografts provide a more pathophysiologically rele-
vant environment for tumor growth. We believe this
model can be adopted to generate new GIST models (i.e.,
KIT exon 9 mutants, PDGFRα mutants, and BRAFV600E
mutants), as well as tumors from non-gastric sites such as
the small bowel, colon, rectum, esophagus, liver, and
peritoneum. However, as previously noted, this model
is limited by significant expense and labor utilization,
as well as technical procedural challenges, the require-
ment for expertise in US, and the requirement for lon-
ger post-procedural healing and recovery. These factors
all contributed to the modest size of our cohort.
In addition to the ability to study tumor biology, such
a model can be applied for drug screening. Imatinib is
considered the first line of treatment for GIST patients
[41]. Unfortunately, once patients develop primary- or
secondary-resistance to this drug, there are limited treat-
ment options. One immediate potential application for
our orthotopic GIST PDXs is the ability to test agents
for efficacy in the setting of imatinib resistance. Hidalgo
et al. reported results from their orthotopic model studies
with advanced solid tumors obtained from 14 patients that
were implanted into immunodeficient mice [42,43]. Once
tumors were established, the mice were treated with 63
drugs in 232 treatment plans. From this murine “clinic
trial,” it was determined that there exists a correlation
between orthotopic PDX killing and clinical efficacy. All
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ance and sensitivity. The data suggests that individual
patient PDXs can be used to personalize a precision treat-
ment approach to treating malignancies. Based upon our
findings, a GIST phenotype can be maintained after at
least 2 passages in our model. Earlier work by Revehim
et al. demonstrated that mutations in KIT exons 11 and 17
were the same in the primary tumor and subcutaneous xe-
nografts after multiple passages in athymic nude mice [44].
Conclusions
In conclusion, we report the first orthotopic patient-
derived xenograft model of human GIST. This novel
approach provides a reproducible model of human GIST
that utilizes the intraperitoneal microenvironment and
maintains the genetic heterogeneity of a human gastro-
intestinal sarcoma. This xenograft model may enhance
our ability to study GIST biology in vivo and serve as a
preclinical platform for testing novel biomarkers and
therapeutics that can inform clinical trial design.
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